secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cocrystal Pharma, Inc. (COCP)
CIK:        0001412486
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0001641172-25-001494
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cocrystal Pharma FY2024 net loss $17.5M; cash $9.9M; pipeline advances
----------------------------------------------------------------------

- Net loss of $17.5M ($1.72 per share) for FY2024, vs. $18.0M ($1.87) in 2023; R&D expenses $12.5M.
- Cash and equivalents $9.9M as of Dec 31 2024, down from $26.4M a year earlier; working capital $9.2M.
- Plans to initiate norovirus human challenge study in U.S. in 2025 for oral pan-viral protease inhibitor CDI-988.
- Will continue Phase 2a influenza challenge study of CC-42344 after low infection rate precluded efficacy data.
- Expects topline results from CDI-988 high-dose cohort in Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1412486/000164117225001494/0001641172-25-001494-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1412486/000164117225001494/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-001494

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer